KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) EBT Margin (2016 - 2025)

Historic EBT Margin for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to 46.87%.

  • Gilead Sciences' EBT Margin rose 342000.0% to 46.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.99%, marking a year-over-year increase of 333700.0%. This contributed to the annual value of 2.4% for FY2024, which is 229000.0% down from last year.
  • Latest data reveals that Gilead Sciences reported EBT Margin of 46.87% as of Q3 2025, which was up 342000.0% from 34.3% recorded in Q2 2025.
  • Gilead Sciences' 5-year EBT Margin high stood at 46.87% for Q3 2025, and its period low was 67.1% during Q1 2024.
  • Over the past 5 years, Gilead Sciences' median EBT Margin value was 27.49% (recorded in 2022), while the average stood at 21.86%.
  • In the last 5 years, Gilead Sciences' EBT Margin tumbled by -875600bps in 2024 and then surged by 918300bps in 2025.
  • Quarter analysis of 5 years shows Gilead Sciences' EBT Margin stood at 10.48% in 2021, then surged by 162bps to 27.49% in 2022, then decreased by -15bps to 23.24% in 2023, then grew by 23bps to 28.63% in 2024, then skyrocketed by 64bps to 46.87% in 2025.
  • Its EBT Margin stands at 46.87% for Q3 2025, versus 34.3% for Q2 2025 and 24.73% for Q1 2025.